^




Show legend
Group by Gene:
Include preclinical:

bevacizumab
Krabeva (bevacizumab biosimilar)
0
VEGF-A inhibitor
Byvasda (bevacizumab biosimilar)
Zirabev (bevacizumab biosimilar)
Mvasi (bevacizumab biosimilar)
temozolomide
1
DNA synthesis inhibitor
dacarbazine
cisplatin
mitomycin
2
Alkylating agent
lomustine
VAL-083
regorafenib
3
Multi-tyrosine kinase inhibitor
anlotinib
pazopanib
ponatinib
4
VEGF-A inhibitor, PIGF inhibitor
aflibercept intravitreal
5
BRAF inhibitor
vemurafenib
dabrafenib
PD1 inhibitor
6
PD1 inhibitor
nivolumab
pembrolizumab
7
Topoisomerase II inhibitor
RTA 744
8
PI3K inhibitor
GDC-0084
9
Immunostimulant, Cell death stimulant
DNX-2401
10
NK cell stimulant
CYNK-001
11
Immunostimulant
VBI-1901
12
ALK inhibitor
crizotinib
13
MEK inhibitor, BRAF inhibitor
BRAF inhibitor + MEK inhibitor
trametinib + dabrafenib
EGFR inhibitor
14
EGFR inhibitor
erlotinib
BDTX-1535
nimotuzumab
15
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
16
HIF-2α inhibitor
belzutifan
17
Integrin inhibitor
cilengitide
18
Reactive oxygen species stimulant, Photosensitizer
verteporfin
19
CXCL12 inhibitor
NOX-A12
20
FGFR antagonist
TAS 120
21
VEGF-A inhibitor, EGFR inhibitor
bevacizumab + osimertinib
bevacizumab + erlotinib
22
VEGFR inhibitor
cediranib
23
MEK inhibitor
PD-0325901
selumetinib
24
DNA synthesis inhibitor, Multi-tyrosine kinase inhibitor
temozolomide + anlotinib
25
mTOR inhibitor
everolimus
26
Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
ABT-414
27
Alkylating agent, DNA synthesis inhibitor
carmustine
temozolomide gel
28
ENO1 inhibitor
ENO1 inhibitor
29
EGFRvIII-targeted CAR-T immunotherapy
EGFRvIII-targeted CAR-T immunotherapy
30
Chemotherapy
PCV
31
Immunotherapy
Immunotherapy
32
Topoisomerase I inhibitor
Topoisomerase I inhibitor
GLR2007
33
CDK4 inhibitor, CDK6 inhibitor
abemaciclib
palbociclib
34
Vascular disrupting agent, Angiogenesis inhibitor
VB-111
35
PI3K inhibitor, PKCβ inhibitor, AKT inhibitor
enzastaurin
36
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor
entrectinib
37
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
38
Thrombospondin-1 stimulant, CD47 inhibitor
VT1021
39
Microtubule destabilizing agent, Vascular disrupting agent, Apoptosis stimulant
BAL101553
40
EphA3 inhibitor, EPH receptor inhibitor
KB004
41
RAS inhibitor, Apoptosis stimulant
NEO100
42
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
43
FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
erdafitinib
44
T-cell stimulant, Wilms tumor 1 inhibitor, PD1 inhibitor, PSMA inhibitor, hTERT inhibitor, IL-12 stimulant
cemiplimab + INO-5401 + INO-9012
45
PD-L1 inhibitor, PI3K inhibitor, AKT inhibitor
atezolizumab + GDC-0068
46
VEGFR inhibitor, HER2 inhibitor, EGFR inhibitor, EphB4 inhibitor
KD019
47
TGFβ inhibitor, PD-L1 inhibitor
M7824
48
HER2 inhibitor, EGFR inhibitor
lapatinib
49
BRAF inhibitor, MEK1 inhibitor
vemurafenib + cobimetinib
50
DNA synthesis inhibitor, PARP inhibitor
temozolomide + ABT-888
51
PKC inhibitor
RO-31-8220
52
VEGF-A inhibitor, PD1 inhibitor
pembrolizumab + bevacizumab
53
PARP inhibitor
olaparib
54
PTP-1B inhibitor
claramine
55
CD133-targeted CAR-T immunotherapy
CD133-specific CAR-T cell therapy
56
CDK2 inhibitor, CDK9 inhibitor, CDK7 inhibitor
CYC065 + SY‑079
57
ROS1 inhibitor, ALK inhibitor
lorlatinib
58
CCR5 receptor antagonist
maraviroc
59
IGF-1R inhibitor
ASP7487
60
VEGF-C inhibitor, NF-κB inhibitor
sodium metaarsenite
61
HDAC inhibitor
MTX110
62
IL-7 agonist
efineptakin alfa
63
Topoisomerase II inhibitor, DNA intercalator
daunorubicin
64
BMI1 inhibitor
PTC-209
65
Tubulin polymerization inhibitor
vincristine
66
Tubulin polymerization promoter
paclitaxel
67
ERK inhibitor, AKT inhibitor
ONC201
68
NEDD8 activating enzyme inhibitor
MLN4924
No biomarker
MGMT unmethylation
MGMT promoter methylation
MGMT underexpression
BRAF V600E
EGFR amplification
EGFR mutation
BRAF V600
EGFR exon 2-7 deletion + EGFR amplification
EGFR expression
EGFR overexpression
EGFRvIII mutation
EGFRvIII expression
FGFR3-TACC3 fusion
IDH1 mutation
IDH2 mutation
TMB-H
MET amplification
MET fusion
TMB-L
IDH1 overexpression
MET overexpression
CXCL10 overexpression
NTRK3 fusion
NTRK1 fusion
NTRK2 fusion
MSI-H/dMMR
PD-L1 expression
VHL mutation
PTEN mutation
MIF overexpression
miR-30b-3p underexpression
CD47 overexpression
TERT 124C>T
CD36 overexpression
PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17)
IDH2 mutation + MGMT promoter methylation
IDH1 mutation + MGMT promoter methylation
HLA-DQA1 overexpression
AGT underexpression
CCL27 overexpression
PIGF-L
EGFRVIII expression + PTEN expression
EPHA3 positive
ABCB1 G412G
IDH1 mutation + WT1 overexpression
IDH2 mutation + MYC amplification + MAPRE1 overexpression
IDH1 mutation + MYC amplification + MAPRE1 overexpression
NF1 deletion
TERT C228T + FGFR3 amplification + FGFR3-TACC3 fusion
BRAF V600E + TERT mutation
TP53 mutation + TSC2 mutation
FGFR1-TACC1 fusion
PIGF overexpression
NF1 470G>T
PIGF elevation
NF1 2195G>T
PTEN deletion
CD44 positive
ATRX mutation
BIRC5 mutation
AIM2 deletion
ROS1 fusion
REST signature
BICD1 overexpression
AKT1 overexpression
PLK2 underexpression
CD8 positive
CTSS overexpression
GSTM1 expression + GSTM5 expression
NGFR expression
BMI1 overexpression
CD133 expression
PGP expression
NCAM1 expression
LIFR expression
FLT1 overexpression
ENO1 deletion
CCL5 overexpression
VEGFA elevation
STAG2 mutation
PTPN1 overexpression
CD133 positive
KDR overexpression
MET overexpression + KDR overexpression
TNFA overexpression
ASAP1 overexpression
AEBP1 overexpression
TERT mutation + MGMT promoter methylation
FLT1 elevation
VEGFA overexpression
CXCL8 overexpression
RB1 expression
EPAS1 overexpression
SETD2 mutation + MGMT promoter methylation
PDGFRA amplification + NTRK2 fusion